Want to see INBS full AI Analyst Report?
INBS Stock Chart & Stats
$2.36
-$0.06(-3.31%)
At close: 4:00 PM EDT
$2.36
-$0.06(-3.31%)
Day’s Range― - ―
52-Week Range$1.52 - $24.90
Previous CloseN/A
Volume62.24K
Average Volume (3M)67.31K
Market Cap
$7.57M
Enterprise Value$0.11
Total Cash (Recent Filing)$3.99M
Total Debt (Recent Filing)$1.82M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 05, 2026EPS Estimate
-1.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.46
Shares Outstanding3,027,470
10 Day Avg. Volume140,200
30 Day Avg. Volume67,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.61
Price to Sales (P/S)0.80
P/FCF Ratio-0.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.18
Revenue Forecast (FY)$6.13M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth indicates improving commercial traction for the fingerprint drug-screening platform. Sustained adoption could expand the installed reader base and recurring cartridge demand, strengthening operating leverage as the business scales.
FDA Submission ReadinessCompletion of the multi-site method comparison study advances the company toward U.S. clearance for codeine detection. FDA authorization could broaden use beyond forensic settings into workplace, corrections and treatment markets.
Potential Manufacturing EconomicsIf realized, the manufacturing partnership could materially improve unit economics and support scalable commercialization. Lower production costs would provide greater flexibility on pricing while helping offset the company’s current margin pressure.
Bears Say
Persistent Cash BurnDeeply negative operating and free cash flow show that the business is not self-funding. Continued investment in regulatory work and commercialization may require additional financing, limiting financial flexibility until recurring revenue scales.
Losses And Margin CompressionLarge losses and falling gross margin indicate that current revenue volume does not cover the cost structure. Unless pricing, mix or production efficiency improves, growth could continue consuming capital rather than creating durable profitability.
Equity Financing And DilutionFunding operations through equity instruments signals dependence on capital markets while cash flow remains negative. A growing share count can dilute existing holders and may constrain per-share participation in future business improvements.
Intelligent Bio Solutions News
INBS FAQ
What was Intelligent Bio Solutions’s price range in the past 12 months?
Intelligent Bio Solutions lowest stock price was $1.52 and its highest was $24.90 in the past 12 months.
What is Intelligent Bio Solutions’s market cap?
Intelligent Bio Solutions’s market cap is $7.57M.
When is Intelligent Bio Solutions’s upcoming earnings report date?
Intelligent Bio Solutions’s upcoming earnings report date is Nov 05, 2026 which is in 71 days.
How were Intelligent Bio Solutions’s earnings last quarter?
Intelligent Bio Solutions released its earnings results on May 13, 2026. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Intelligent Bio Solutions overvalued?
According to Wall Street analysts Intelligent Bio Solutions’s price is currently Overvalued.
Does Intelligent Bio Solutions pay dividends?
Intelligent Bio Solutions does not currently pay dividends.
What is Intelligent Bio Solutions’s EPS estimate?
Intelligent Bio Solutions’s EPS estimate is -1.31.
How many shares outstanding does Intelligent Bio Solutions have?
Intelligent Bio Solutions has 3,027,470 shares outstanding.
What happened to Intelligent Bio Solutions’s price movement after its last earnings report?
Intelligent Bio Solutions reported an EPS of -$1.8 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 25.472%.
Which hedge fund is a major shareholder of Intelligent Bio Solutions?
Currently, no hedge funds are holding shares in INBS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intelligent Bio Solutions
Intelligent Bio Solutions Inc. operates as a life sciences firm focused on developing non-invasive, real-time monitoring and diagnostic solutions for both patients and their primary healthcare providers. A notable product in its portfolio is the Saliva Glucose Biosensor, an organic thin-film transistor designed to precisely measure glucose levels in saliva for effective diabetes management. Beyond this, the company is actively developing a SARS-CoV-2 Biosensor, intended to serve as a supplementary diagnostic tool to existing RNA virus detection methods. It also maintains a broad biosensor platform that encompasses diverse diagnostic modalities, including biochemistry, immunology, tumor marker identification, hormone analysis, and nucleic acid diagnostics. Incorporated in 2016 and based in New York, New York, the company was formerly known as GBS Inc. before adopting its current name in October 2022. Intelligent Bio Solutions Inc. operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Technical Analysis
Ownership Overview
2.99% Insiders
0.50% Mutual Funds
4.67% Other Institutional Investors
91.65% Public Companies and
Individual Investors